Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B

Continued here:
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh